Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2021-11-10

AUTHORS

Dikshyanta Rana, Claudia Geue, Kelly Baillie, Jiafeng Pan, Tanja Mueller, Jennifer Laskey, Marion Bennie, Julie Clarke, Robert J. Jones, Ailsa Brown, Olivia Wu

ABSTRACT

ObjectiveThe aim was to assess the real-world healthcare resource use and direct medical costs for metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone or enzalutamide, in whom chemotherapy is not yet indicated (pre-chemotherapy) or who had previously received docetaxel-based chemotherapy (post-chemotherapy), before commencing these medicines.MethodsA retrospective cost analysis of mCRPC patients who commenced abiraterone or enzalutamide between 2012 and 2015 was conducted. Routinely collected datasets from the largest health board in Scotland and the UK, Greater Glasgow and Clyde, were linked. They contained information on patient demographics, diagnosis, outpatient consultations, hospital admissions, treatments (abiraterone and enzalutamide), and supportive medicines. Unit costs were obtained from the Scottish Health Service Costs, Personal Social Services Research Unit, and British National Formulary. Generalised linear model-based regression was used to estimate total mean direct costs, and two-part models were used to estimate separate cost components. All models were adjusted for propensity score and key variables. Sensitivity analysis was conducted to explore the impact of hypothetical patient access scheme discounts.ResultsEstimated total mean direct medical costs of treating mCRPC patients were similar, albeit with wide and overlapping confidence intervals. Across both treatments, patients who received abiraterone or enzalutamide in a pre-chemotherapy setting incurred the highest total mean direct medical costs. However, post-chemotherapy patients were associated with higher outpatient clinic visits, inpatient hospital admissions, and supportive medicines. Regarding relative contribution to the total mean direct medical cost, the treatment costs were the main contributor, followed by inpatient admissions, outpatient clinic visits, and supportive medicines.ConclusionThe total mean direct medical costs were similar for abiraterone and enzalutamide patients. The costs were not driven by the choice of treatment regimen, but treatment setting (pre-chemotherapy or post-chemotherapy indications) and related healthcare resource utilisation. Future studies should focus on economic evaluations, such as cost-effectiveness analyses, using real-world data. More... »

PAGES

1-11

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s41669-021-00307-1

DOI

http://dx.doi.org/10.1007/s41669-021-00307-1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1142518898

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/34761368


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/14", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Economics", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1402", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Applied Economics", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Health Economics and Health Technology Assessment (HEHTA), Institute of Health and Wellbeing, University of Glasgow, 1 Lilybank Gardens, G12 8RZ, Glasgow, UK", 
          "id": "http://www.grid.ac/institutes/grid.8756.c", 
          "name": [
            "Health Economics and Health Technology Assessment (HEHTA), Institute of Health and Wellbeing, University of Glasgow, 1 Lilybank Gardens, G12 8RZ, Glasgow, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rana", 
        "givenName": "Dikshyanta", 
        "id": "sg:person.012122736535.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012122736535.18"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Health Economics and Health Technology Assessment (HEHTA), Institute of Health and Wellbeing, University of Glasgow, 1 Lilybank Gardens, G12 8RZ, Glasgow, UK", 
          "id": "http://www.grid.ac/institutes/grid.8756.c", 
          "name": [
            "Health Economics and Health Technology Assessment (HEHTA), Institute of Health and Wellbeing, University of Glasgow, 1 Lilybank Gardens, G12 8RZ, Glasgow, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Geue", 
        "givenName": "Claudia", 
        "id": "sg:person.01330072543.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01330072543.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Beatson West of Scotland Cancer Centre, NHS Greater Glasgow and Clyde, Glasgow, UK", 
          "id": "http://www.grid.ac/institutes/grid.413301.4", 
          "name": [
            "Beatson West of Scotland Cancer Centre, NHS Greater Glasgow and Clyde, Glasgow, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Baillie", 
        "givenName": "Kelly", 
        "id": "sg:person.015312777073.71", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015312777073.71"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Mathematics and Statistics, University of Strathclyde, Glasgow, UK", 
          "id": "http://www.grid.ac/institutes/grid.11984.35", 
          "name": [
            "Department of Mathematics and Statistics, University of Strathclyde, Glasgow, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pan", 
        "givenName": "Jiafeng", 
        "id": "sg:person.01251240125.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01251240125.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK", 
          "id": "http://www.grid.ac/institutes/grid.11984.35", 
          "name": [
            "Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mueller", 
        "givenName": "Tanja", 
        "id": "sg:person.012046306577.92", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012046306577.92"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Beatson West of Scotland Cancer Centre, NHS Greater Glasgow and Clyde, Glasgow, UK", 
          "id": "http://www.grid.ac/institutes/grid.413301.4", 
          "name": [
            "Beatson West of Scotland Cancer Centre, NHS Greater Glasgow and Clyde, Glasgow, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Laskey", 
        "givenName": "Jennifer", 
        "id": "sg:person.010144552053.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010144552053.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinical and Protecting Health Directorate, Public Health Scotland, Edinburgh, UK", 
          "id": "http://www.grid.ac/institutes/grid.508718.3", 
          "name": [
            "Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK", 
            "Clinical and Protecting Health Directorate, Public Health Scotland, Edinburgh, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bennie", 
        "givenName": "Marion", 
        "id": "sg:person.0761135000.02", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0761135000.02"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Beatson West of Scotland Cancer Centre, NHS Greater Glasgow and Clyde, Glasgow, UK", 
          "id": "http://www.grid.ac/institutes/grid.413301.4", 
          "name": [
            "Beatson West of Scotland Cancer Centre, NHS Greater Glasgow and Clyde, Glasgow, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Clarke", 
        "givenName": "Julie", 
        "id": "sg:person.013227622115.58", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013227622115.58"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institute of Cancer Sciences, University of Glasgow, Glasgow, UK", 
          "id": "http://www.grid.ac/institutes/grid.8756.c", 
          "name": [
            "Beatson West of Scotland Cancer Centre, NHS Greater Glasgow and Clyde, Glasgow, UK", 
            "Institute of Cancer Sciences, University of Glasgow, Glasgow, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jones", 
        "givenName": "Robert J.", 
        "id": "sg:person.0737650202.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0737650202.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Healthcare Improvement Scotland, Glasgow, UK", 
          "id": "http://www.grid.ac/institutes/grid.482042.8", 
          "name": [
            "Healthcare Improvement Scotland, Glasgow, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Brown", 
        "givenName": "Ailsa", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Health Economics and Health Technology Assessment (HEHTA), Institute of Health and Wellbeing, University of Glasgow, 1 Lilybank Gardens, G12 8RZ, Glasgow, UK", 
          "id": "http://www.grid.ac/institutes/grid.8756.c", 
          "name": [
            "Health Economics and Health Technology Assessment (HEHTA), Institute of Health and Wellbeing, University of Glasgow, 1 Lilybank Gardens, G12 8RZ, Glasgow, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wu", 
        "givenName": "Olivia", 
        "id": "sg:person.01351604417.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01351604417.18"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s12094-018-1921-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1105679843", 
          "https://doi.org/10.1007/s12094-018-1921-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s41669-020-00219-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1128064518", 
          "https://doi.org/10.1007/s41669-020-00219-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12325-018-0774-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106829809", 
          "https://doi.org/10.1007/s12325-018-0774-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12325-020-01260-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1125142873", 
          "https://doi.org/10.1007/s12325-020-01260-x"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2021-11-10", 
    "datePublishedReg": "2021-11-10", 
    "description": "ObjectiveThe aim was to assess the real-world healthcare resource use and direct medical costs for metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone or enzalutamide, in whom chemotherapy is not yet indicated (pre-chemotherapy) or who had previously received docetaxel-based chemotherapy (post-chemotherapy), before commencing these medicines.MethodsA retrospective cost analysis of mCRPC patients who commenced abiraterone or enzalutamide between 2012 and 2015 was conducted. Routinely collected datasets from the largest health board in Scotland and the UK, Greater Glasgow and Clyde, were linked. They contained information on patient demographics, diagnosis, outpatient consultations, hospital admissions, treatments (abiraterone and enzalutamide), and supportive medicines. Unit costs were obtained from the Scottish Health Service Costs, Personal Social Services Research Unit, and British National Formulary. Generalised linear model-based regression was used to estimate total mean direct costs, and two-part models were used to estimate separate cost components. All models were adjusted for propensity score and key variables. Sensitivity analysis was conducted to explore the impact of hypothetical patient access scheme discounts.ResultsEstimated total mean direct medical costs of treating mCRPC patients were similar, albeit with wide and overlapping confidence intervals. Across both treatments, patients who received abiraterone or enzalutamide in a pre-chemotherapy setting incurred the highest total mean direct medical costs. However, post-chemotherapy patients were associated with higher outpatient clinic visits, inpatient hospital admissions, and supportive medicines. Regarding relative contribution to the total mean direct medical cost, the treatment costs were the main contributor, followed by inpatient admissions, outpatient clinic visits, and supportive medicines.ConclusionThe total mean direct medical costs were similar for abiraterone and enzalutamide patients. The costs were not driven by the choice of treatment regimen, but treatment setting (pre-chemotherapy or post-chemotherapy indications) and related healthcare resource utilisation. Future studies should focus on economic evaluations, such as cost-effectiveness analyses, using real-world data.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s41669-021-00307-1", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1284515", 
        "issn": [
          "2509-4262", 
          "2509-4254"
        ], 
        "name": "PharmacoEconomics - Open", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }
    ], 
    "keywords": [
      "direct medical costs", 
      "metastatic castration-resistant prostate cancer patients", 
      "castration-resistant prostate cancer patients", 
      "outpatient clinic visits", 
      "prostate cancer patients", 
      "medical costs", 
      "supportive medicine", 
      "mCRPC patients", 
      "hospital admission", 
      "clinic visits", 
      "cancer patients", 
      "mean direct medical cost", 
      "healthcare resource utilisation", 
      "healthcare resource use", 
      "docetaxel-based chemotherapy", 
      "inpatient hospital admissions", 
      "post-chemotherapy patients", 
      "health service costs", 
      "British National Formulary", 
      "retrospective cost analysis", 
      "large health board", 
      "cost-effectiveness analysis", 
      "Personal Social Services Research Unit", 
      "patient demographics", 
      "treatment regimen", 
      "inpatient admissions", 
      "outpatient consultations", 
      "ObjectiveThe aim", 
      "abiraterone", 
      "Greater Glasgow", 
      "healthcare costs", 
      "patients", 
      "treatment settings", 
      "Health Board", 
      "propensity score", 
      "National Formulary", 
      "admission", 
      "treatment costs", 
      "direct costs", 
      "confidence intervals", 
      "chemotherapy", 
      "two-part model", 
      "visits", 
      "future studies", 
      "medicine", 
      "treatment", 
      "economic evaluation", 
      "resource utilisation", 
      "enzalutamide", 
      "regimen", 
      "Research Unit", 
      "resource use", 
      "diagnosis", 
      "formulary", 
      "demographics", 
      "service costs", 
      "consultation", 
      "scores", 
      "total", 
      "cost analysis", 
      "relative contribution", 
      "regression", 
      "aim", 
      "setting", 
      "intervals", 
      "unit cost", 
      "main contributor", 
      "evaluation", 
      "analysis", 
      "study", 
      "sensitivity analysis", 
      "Glasgow", 
      "contributor", 
      "real-world data", 
      "use", 
      "cost components", 
      "UK", 
      "model-based regression", 
      "utilisation", 
      "data", 
      "variables", 
      "units", 
      "impact", 
      "cost", 
      "choice", 
      "model", 
      "key variables", 
      "Scotland", 
      "information", 
      "components", 
      "discount", 
      "board", 
      "contribution", 
      "Clyde", 
      "dataset", 
      "real-world healthcare resource use", 
      "Scottish Health Service Costs", 
      "Social Services Research Unit", 
      "Services Research Unit", 
      "linear model-based regression", 
      "separate cost components", 
      "hypothetical patient access scheme discounts", 
      "patient access scheme discounts", 
      "access scheme discounts", 
      "scheme discounts", 
      "ResultsEstimated total", 
      "highest total mean direct medical costs", 
      "total mean direct medical costs", 
      "higher outpatient clinic visits", 
      "related healthcare resource utilisation"
    ], 
    "name": "Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide", 
    "pagination": "1-11", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1142518898"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s41669-021-00307-1"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "34761368"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s41669-021-00307-1", 
      "https://app.dimensions.ai/details/publication/pub.1142518898"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T19:00", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_915.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s41669-021-00307-1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s41669-021-00307-1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s41669-021-00307-1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s41669-021-00307-1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s41669-021-00307-1'


 

This table displays all metadata directly associated to this object as RDF triples.

277 TRIPLES      22 PREDICATES      140 URIs      126 LITERALS      5 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s41669-021-00307-1 schema:about anzsrc-for:11
2 anzsrc-for:1117
3 anzsrc-for:14
4 anzsrc-for:1402
5 schema:author N74ea4c92275c43f99a82966c36c11d0e
6 schema:citation sg:pub.10.1007/s12094-018-1921-5
7 sg:pub.10.1007/s12325-018-0774-1
8 sg:pub.10.1007/s12325-020-01260-x
9 sg:pub.10.1007/s41669-020-00219-6
10 schema:datePublished 2021-11-10
11 schema:datePublishedReg 2021-11-10
12 schema:description ObjectiveThe aim was to assess the real-world healthcare resource use and direct medical costs for metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone or enzalutamide, in whom chemotherapy is not yet indicated (pre-chemotherapy) or who had previously received docetaxel-based chemotherapy (post-chemotherapy), before commencing these medicines.MethodsA retrospective cost analysis of mCRPC patients who commenced abiraterone or enzalutamide between 2012 and 2015 was conducted. Routinely collected datasets from the largest health board in Scotland and the UK, Greater Glasgow and Clyde, were linked. They contained information on patient demographics, diagnosis, outpatient consultations, hospital admissions, treatments (abiraterone and enzalutamide), and supportive medicines. Unit costs were obtained from the Scottish Health Service Costs, Personal Social Services Research Unit, and British National Formulary. Generalised linear model-based regression was used to estimate total mean direct costs, and two-part models were used to estimate separate cost components. All models were adjusted for propensity score and key variables. Sensitivity analysis was conducted to explore the impact of hypothetical patient access scheme discounts.ResultsEstimated total mean direct medical costs of treating mCRPC patients were similar, albeit with wide and overlapping confidence intervals. Across both treatments, patients who received abiraterone or enzalutamide in a pre-chemotherapy setting incurred the highest total mean direct medical costs. However, post-chemotherapy patients were associated with higher outpatient clinic visits, inpatient hospital admissions, and supportive medicines. Regarding relative contribution to the total mean direct medical cost, the treatment costs were the main contributor, followed by inpatient admissions, outpatient clinic visits, and supportive medicines.ConclusionThe total mean direct medical costs were similar for abiraterone and enzalutamide patients. The costs were not driven by the choice of treatment regimen, but treatment setting (pre-chemotherapy or post-chemotherapy indications) and related healthcare resource utilisation. Future studies should focus on economic evaluations, such as cost-effectiveness analyses, using real-world data.
13 schema:genre article
14 schema:inLanguage en
15 schema:isAccessibleForFree true
16 schema:isPartOf sg:journal.1284515
17 schema:keywords British National Formulary
18 Clyde
19 Glasgow
20 Greater Glasgow
21 Health Board
22 National Formulary
23 ObjectiveThe aim
24 Personal Social Services Research Unit
25 Research Unit
26 ResultsEstimated total
27 Scotland
28 Scottish Health Service Costs
29 Services Research Unit
30 Social Services Research Unit
31 UK
32 abiraterone
33 access scheme discounts
34 admission
35 aim
36 analysis
37 board
38 cancer patients
39 castration-resistant prostate cancer patients
40 chemotherapy
41 choice
42 clinic visits
43 components
44 confidence intervals
45 consultation
46 contribution
47 contributor
48 cost
49 cost analysis
50 cost components
51 cost-effectiveness analysis
52 data
53 dataset
54 demographics
55 diagnosis
56 direct costs
57 direct medical costs
58 discount
59 docetaxel-based chemotherapy
60 economic evaluation
61 enzalutamide
62 evaluation
63 formulary
64 future studies
65 health service costs
66 healthcare costs
67 healthcare resource use
68 healthcare resource utilisation
69 higher outpatient clinic visits
70 highest total mean direct medical costs
71 hospital admission
72 hypothetical patient access scheme discounts
73 impact
74 information
75 inpatient admissions
76 inpatient hospital admissions
77 intervals
78 key variables
79 large health board
80 linear model-based regression
81 mCRPC patients
82 main contributor
83 mean direct medical cost
84 medical costs
85 medicine
86 metastatic castration-resistant prostate cancer patients
87 model
88 model-based regression
89 outpatient clinic visits
90 outpatient consultations
91 patient access scheme discounts
92 patient demographics
93 patients
94 post-chemotherapy patients
95 propensity score
96 prostate cancer patients
97 real-world data
98 real-world healthcare resource use
99 regimen
100 regression
101 related healthcare resource utilisation
102 relative contribution
103 resource use
104 resource utilisation
105 retrospective cost analysis
106 scheme discounts
107 scores
108 sensitivity analysis
109 separate cost components
110 service costs
111 setting
112 study
113 supportive medicine
114 total
115 total mean direct medical costs
116 treatment
117 treatment costs
118 treatment regimen
119 treatment settings
120 two-part model
121 unit cost
122 units
123 use
124 utilisation
125 variables
126 visits
127 schema:name Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
128 schema:pagination 1-11
129 schema:productId N0215e902413a45e7a9698ea526929327
130 N20f93e8626ff4a2b8938857b85eaabf6
131 N53792e8699a04be78ff60cfb33b6b280
132 schema:sameAs https://app.dimensions.ai/details/publication/pub.1142518898
133 https://doi.org/10.1007/s41669-021-00307-1
134 schema:sdDatePublished 2022-01-01T19:00
135 schema:sdLicense https://scigraph.springernature.com/explorer/license/
136 schema:sdPublisher N42d03e18f49c44d790f4b89f42152e94
137 schema:url https://doi.org/10.1007/s41669-021-00307-1
138 sgo:license sg:explorer/license/
139 sgo:sdDataset articles
140 rdf:type schema:ScholarlyArticle
141 N0215e902413a45e7a9698ea526929327 schema:name pubmed_id
142 schema:value 34761368
143 rdf:type schema:PropertyValue
144 N072e53a056174cd0b3176e55ba1ead11 rdf:first sg:person.01351604417.18
145 rdf:rest rdf:nil
146 N20f93e8626ff4a2b8938857b85eaabf6 schema:name dimensions_id
147 schema:value pub.1142518898
148 rdf:type schema:PropertyValue
149 N3953645dcee4480a909a49dc0eddd302 rdf:first sg:person.013227622115.58
150 rdf:rest N40e834cda81a4cbf949a11c061f65694
151 N3d0dbdbd00474b1780749ee8949e487a rdf:first sg:person.015312777073.71
152 rdf:rest N6339b1b6a6be47038d6da00436e88094
153 N40e834cda81a4cbf949a11c061f65694 rdf:first sg:person.0737650202.16
154 rdf:rest Nc17ba0754c2b4c15a2ac459940bac198
155 N42d03e18f49c44d790f4b89f42152e94 schema:name Springer Nature - SN SciGraph project
156 rdf:type schema:Organization
157 N53792e8699a04be78ff60cfb33b6b280 schema:name doi
158 schema:value 10.1007/s41669-021-00307-1
159 rdf:type schema:PropertyValue
160 N6339b1b6a6be47038d6da00436e88094 rdf:first sg:person.01251240125.41
161 rdf:rest Nccac264c9f6641bb8f1d06a2de3a550b
162 N6e2ac93d050841a6800733feb2d69e6c rdf:first sg:person.010144552053.46
163 rdf:rest Ne949c51e359c476ebf673cce772974d1
164 N74ea4c92275c43f99a82966c36c11d0e rdf:first sg:person.012122736535.18
165 rdf:rest Nc9e43a6be9344c75b77d786aae738b52
166 Nc17ba0754c2b4c15a2ac459940bac198 rdf:first Nd59285e5e28e42738f4352e82d4865c9
167 rdf:rest N072e53a056174cd0b3176e55ba1ead11
168 Nc9e43a6be9344c75b77d786aae738b52 rdf:first sg:person.01330072543.23
169 rdf:rest N3d0dbdbd00474b1780749ee8949e487a
170 Nccac264c9f6641bb8f1d06a2de3a550b rdf:first sg:person.012046306577.92
171 rdf:rest N6e2ac93d050841a6800733feb2d69e6c
172 Nd59285e5e28e42738f4352e82d4865c9 schema:affiliation grid-institutes:grid.482042.8
173 schema:familyName Brown
174 schema:givenName Ailsa
175 rdf:type schema:Person
176 Ne949c51e359c476ebf673cce772974d1 rdf:first sg:person.0761135000.02
177 rdf:rest N3953645dcee4480a909a49dc0eddd302
178 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
179 schema:name Medical and Health Sciences
180 rdf:type schema:DefinedTerm
181 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
182 schema:name Public Health and Health Services
183 rdf:type schema:DefinedTerm
184 anzsrc-for:14 schema:inDefinedTermSet anzsrc-for:
185 schema:name Economics
186 rdf:type schema:DefinedTerm
187 anzsrc-for:1402 schema:inDefinedTermSet anzsrc-for:
188 schema:name Applied Economics
189 rdf:type schema:DefinedTerm
190 sg:journal.1284515 schema:issn 2509-4254
191 2509-4262
192 schema:name PharmacoEconomics - Open
193 schema:publisher Springer Nature
194 rdf:type schema:Periodical
195 sg:person.010144552053.46 schema:affiliation grid-institutes:grid.413301.4
196 schema:familyName Laskey
197 schema:givenName Jennifer
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010144552053.46
199 rdf:type schema:Person
200 sg:person.012046306577.92 schema:affiliation grid-institutes:grid.11984.35
201 schema:familyName Mueller
202 schema:givenName Tanja
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012046306577.92
204 rdf:type schema:Person
205 sg:person.012122736535.18 schema:affiliation grid-institutes:grid.8756.c
206 schema:familyName Rana
207 schema:givenName Dikshyanta
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012122736535.18
209 rdf:type schema:Person
210 sg:person.01251240125.41 schema:affiliation grid-institutes:grid.11984.35
211 schema:familyName Pan
212 schema:givenName Jiafeng
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01251240125.41
214 rdf:type schema:Person
215 sg:person.013227622115.58 schema:affiliation grid-institutes:grid.413301.4
216 schema:familyName Clarke
217 schema:givenName Julie
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013227622115.58
219 rdf:type schema:Person
220 sg:person.01330072543.23 schema:affiliation grid-institutes:grid.8756.c
221 schema:familyName Geue
222 schema:givenName Claudia
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01330072543.23
224 rdf:type schema:Person
225 sg:person.01351604417.18 schema:affiliation grid-institutes:grid.8756.c
226 schema:familyName Wu
227 schema:givenName Olivia
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01351604417.18
229 rdf:type schema:Person
230 sg:person.015312777073.71 schema:affiliation grid-institutes:grid.413301.4
231 schema:familyName Baillie
232 schema:givenName Kelly
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015312777073.71
234 rdf:type schema:Person
235 sg:person.0737650202.16 schema:affiliation grid-institutes:grid.8756.c
236 schema:familyName Jones
237 schema:givenName Robert J.
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0737650202.16
239 rdf:type schema:Person
240 sg:person.0761135000.02 schema:affiliation grid-institutes:grid.508718.3
241 schema:familyName Bennie
242 schema:givenName Marion
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0761135000.02
244 rdf:type schema:Person
245 sg:pub.10.1007/s12094-018-1921-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1105679843
246 https://doi.org/10.1007/s12094-018-1921-5
247 rdf:type schema:CreativeWork
248 sg:pub.10.1007/s12325-018-0774-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106829809
249 https://doi.org/10.1007/s12325-018-0774-1
250 rdf:type schema:CreativeWork
251 sg:pub.10.1007/s12325-020-01260-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1125142873
252 https://doi.org/10.1007/s12325-020-01260-x
253 rdf:type schema:CreativeWork
254 sg:pub.10.1007/s41669-020-00219-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1128064518
255 https://doi.org/10.1007/s41669-020-00219-6
256 rdf:type schema:CreativeWork
257 grid-institutes:grid.11984.35 schema:alternateName Department of Mathematics and Statistics, University of Strathclyde, Glasgow, UK
258 Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK
259 schema:name Department of Mathematics and Statistics, University of Strathclyde, Glasgow, UK
260 Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK
261 rdf:type schema:Organization
262 grid-institutes:grid.413301.4 schema:alternateName Beatson West of Scotland Cancer Centre, NHS Greater Glasgow and Clyde, Glasgow, UK
263 schema:name Beatson West of Scotland Cancer Centre, NHS Greater Glasgow and Clyde, Glasgow, UK
264 rdf:type schema:Organization
265 grid-institutes:grid.482042.8 schema:alternateName Healthcare Improvement Scotland, Glasgow, UK
266 schema:name Healthcare Improvement Scotland, Glasgow, UK
267 rdf:type schema:Organization
268 grid-institutes:grid.508718.3 schema:alternateName Clinical and Protecting Health Directorate, Public Health Scotland, Edinburgh, UK
269 schema:name Clinical and Protecting Health Directorate, Public Health Scotland, Edinburgh, UK
270 Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK
271 rdf:type schema:Organization
272 grid-institutes:grid.8756.c schema:alternateName Health Economics and Health Technology Assessment (HEHTA), Institute of Health and Wellbeing, University of Glasgow, 1 Lilybank Gardens, G12 8RZ, Glasgow, UK
273 Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
274 schema:name Beatson West of Scotland Cancer Centre, NHS Greater Glasgow and Clyde, Glasgow, UK
275 Health Economics and Health Technology Assessment (HEHTA), Institute of Health and Wellbeing, University of Glasgow, 1 Lilybank Gardens, G12 8RZ, Glasgow, UK
276 Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
277 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...